Psychiatry

Solriamfetol could potentially serve as a new ADHD treatment if future research goes positively.

Solriamfetol, typically used to treat narcolepsy and sleep apnea, has demonstrated it can reduce ADHD symptoms with no adverse cardiovascular effects.

Participants with PTSD in a new study heard voices more significantly than did patients with schizophrenia and schizoaffective disorder, according to investigators.

A new analysis was unable to provide conclusive comparisons between the 2 methods of psychotherapy delivery, despite robust data.

Regarding teachers’ responses to handle anxiety in students with autism spectrum disorder, 33.3% teachers promote anxiety and 37.1% promote autonomy.

A trend shows there is an association between the rise of LSD and adults with depression—but it is even more prevalent in young adults aged 18-34 than older adults.

Only roughly 21% of adolescents with mental health issues receive outpatient treatment, according to a new study.

95% of the veterans who screened positive for PTSD also screened positive for insomnia, showing how PTSD is linked to insomnia.

Children and adolescents with autism spectrum disorder have less physical activity, longer sleep latency, shorter total sleep time, and lower sleep efficiency than their peers without autism.

A newly developed prediction model for opioid treatment relapse includes 4 consecutive week urine drug screenings to test for risk of return.

Extended-release quetiapine is commonly used for treatment-resistant depression, but a new study reveals patients receiving esketamine nasal spray are 54% more likely to reach remission at 8 weeks.

Race/ethnicity, parental education, household income, housing tenure, household food sufficiency, and health insurance coverage are all factors linked to the likelihood of mental health challenges in children and adolescents.

In a new study, 50% of adolescents admitted into a psychiatric hospital screened positive for insomnia.

The COVID-19 pandemic skyrocketed already high rates of alcohol consumption and related liver disease to unprecedented levels. Addiction specialists and hepatologists are still looking for the best path out.

Investigators of a new meta-analysis designed the Psymatik Treatment Optimizer, an online tool which synthesizes side-effects in a database and can personalize individual user side effect concerns.

Gradually reducing antipsychotic dosage increases the risk of relapse for people with psychotic disorders and does not improve social functioning.

New data show children with higher baseline adaptative functioning scores, as well as girls, were more likely to have nonpersistent autism spectrum disorder in later years.

Multiple cohorts of health care professions, including registered nurses and social/behavioral workers, are at greater risk of suicide than the general population, according to new data.

When cognitively healthy older adults performed a road test when taking a medicine with adverse effects, 35% of participants received a marginal/fail rating.

Investigators believe their findings may help reduce the negative of self-stigma and subjective symptom reporting burdening patients with depression.

The indication is the first for an antidepressant that selectively targets the serotonin 1A receptor—a regulator of mood and emotion.

A new study reveals pleasant stimuli brings less joy to people with schizophrenia or those who have a risk of psychosis.

New data from Sweden conflict with previous register-based research showing a “substantially” increased risk of mania among antidepressant-treated pediatric patients with unipolar depression.

A new literature review shows that globally, a majority of both men and women with schizophrenia experience some form of sexual dysfunction.

New 3-year analysis shows a significant rate of patients were able to avoid relapse or hospitalization while receiving the long-acting injectable.

A recently authorized device for autism detection showed promising accuracy in research across US specialty clinics. The lead author shares his thoughts on a new podcast.

New phase 2 data adds to the growing interest in the psychedelic treatment as a novel drug to treat MDD.

A prospective cohort analysis of pregnant women in Rotterdam shows a potential link between the popular drug class and emotional regulation development trajectories.

A study of 7 million-plus US adults shows telehealth visits for mental health conditions increased more than 10-fold during the COVID-19 pandemic.

A large systematic review assessing more than 60 drugs for bipolar depression shows only a handful were statistically signifcantly better than placebo per depressive symptom outcomes.